Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
A Phase 2, Multicenter, Open-label Study to Evaluate the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
Sponsor: Rallybio
Terminated
This study was terminated early by the sponsor due to insufficient drug exposure to achieve the intended therapeutic effect.
Listed as NCT06435845, this PHASE2 trial focuses on Fetal and Neonatal Alloimmune Thrombocytopenia and remains terminated or withdrawn. Sponsored by Rallybio, it has been updated 10 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Mar 2026 — Present [monthly]
Terminated PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Jul 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Feb 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Rallybio
For direct contact, visit the study record on ClinicalTrials.gov .